While Rx drug pricing is under attack by Congress, White House and consumer and public health advocacy groups, OTC drugs' value isn't gaining a higher profile. "Our health care system undervalues the contribution of our industry's products," says CHPA chief Scott Melville. Trade group conducts “Value of OTC Medicines" study for reasons including raising the profile of consumer health products in the US health care system.
The Consumer Healthcare Products Association's latest survey to quantify the value of OTC drugs to US health care suggests total annual savings o the system increased by nearly $45bn since its previous research.
While the trade group conducted its previous “Value of OTC Medicines to the U.S. Healthcare System" in 2012 for reasons...